Diebold Nixdorf (DBD) Misses Q2 EPS by 13c ; Offers Guidance

Diebold Nixdorf (NYSE: DBD) reported Q2 EPS of $1.10, $0.13 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $930.8 million.

GUIDANCE:

Diebold Nixdorf sees FY2026 EPS of $5.25-$5.75, versus the consensus of $5.49. Diebold Nixdorf sees FY2026 revenue of $3.86-3.94 billion, versus the consensus of $3.91 billion.

For earnings history and earnings-related data on Diebold Nixdorf (DBD) click here.

You May Also Be Interested In

• ArriVent BioPharma (AVBP) Reiterated at Overweight by Cantor Fitzgerald
• Tyra Biosciences (TYRA) PT Lowered to $29 at H.C. Wainwright
• Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate